MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
DexCom Interest Expense 2011-2026 | DXCM
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 M | 109 M | 113 M | 18.6 M | 18.8 M | 17.7 M | 60.3 M | 22.7 M | 12.8 M | 700 K | 400 K | 800 K | 900 K | 200 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | 200 K | 39.4 M |
Quarterly Interest Expense DexCom
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | - | 28.5 M | 20.6 M | - | 25.4 M | 29.8 M | 31.4 M | - | 34.9 M | 31.2 M | 4.6 M | - | 4.6 M | 4.7 M | 4.6 M | - | 4.6 M | 25.2 M | 4.7 M | - | 24.4 M | 20.3 M | 15.4 M | - | 15.1 M | 15 M | 14.9 M | - | 4.9 M | 4.8 M | 4.8 M | - | 4.5 M | 3.1 M | 500 K | - | 200 K | 100 K | 100 K | - | 100 K | 100 K | 200 K | - | 200 K | 200 K | 200 K | - | 200 K | 200 K | 200 K | - | - | - | - | - | 1 K | 3 K | 6 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.9 M | 1 K | 9.49 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Castle Biosciences
CSTL
|
144 K | $ 20.15 | -1.9 % | $ 584 M |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 118.95 | 0.8 % | $ 14.9 B | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 17.11 | -1.55 % | $ 517 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 116.78 | 0.18 % | $ 9.63 B |  Irlanda |
 |
Agilent Technologies
A
|
81 M | $ 114.96 | 0.15 % | $ 34.9 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 138.23 | -3.02 % | $ 6.46 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 5.07 | 36.66 % | $ 6.74 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 21.63 | 0.28 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 144.41 | -0.29 % | $ 23 B | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.82 | 1.11 % | $ 8.05 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 103.0 | 9.03 % | $ 6.95 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 432.8 | 0.63 % | $ 12.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 103.09 | 1.16 % | $ 22.7 B |  Schweiz |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 160.3 | 0.91 % | $ 7.95 B | USA |
 |
Personalis
PSNL
|
205 K | $ 8.47 | 2.67 % | $ 756 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.23 | 1.32 % | $ 1.18 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 19.08 | 0.21 % | $ 427 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 203.19 | -0.25 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 3.82 | -2.3 % | $ 354 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.95 | -0.74 % | $ 25.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.34 | 2.92 % | $ 265 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 60.57 | 2.95 % | $ 3.62 B | USA |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.49 | 2.05 % | $ 5.72 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 259.93 | 1.63 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 448.28 | -0.24 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.6 | -3.7 % | $ 216 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.9 | 0.45 % | $ 1.93 B | USA |
 |
Waters Corporation
WAT
|
14.3 M | $ 342.37 | 0.4 % | $ 20.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.21 | 0.72 % | $ 21.7 B | USA |